What the FDA labels say about taking them together
Hydroxyurea and valganciclovir
Valganciclovir's FDA label of December 8, 2025 names hydroxyurea in its drug interactions section; the hydroxyurea labels PlainMeds reads (3) do not name valganciclovir. The valganciclovir label: “Because of potential for higher toxicity, coadministration with VALCYTE should be considered only if the potential benefits are judged to outweigh the risks.”
Check it at the source: the hydroxyurea FDA label on DailyMed (effective September 15, 2025, Waylis Therapeutics LLC); the valganciclovir FDA label on DailyMed (effective December 8, 2025, H2-Pharma, LLC).
What does the hydroxyurea label say about valganciclovir?
Hydroxyurea's label (effective September 15, 2025) and its 2 other brand-application labels do not name valganciclovir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (HYDREA), Waylis Therapeutics LLC, effective September 15, 2025 (SPL set 8d41152f-a98a-4abc-afdf-a909012434a0), via openFDA; the full label on DailyMed
What does the valganciclovir label say about hydroxyurea?
Valganciclovir label, drug interactionsName of the Concomitant Drug: Other drugs associated with myelosuppression or nephrotoxicity (e.g., adriamycin, dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole, vinblastine, vincristine, and zidovudine); Change in the Concentration of Ganciclovir or Concomitant Drug: Unknown; Clinical Comment: Because of potential for higher toxicity, coadministration with VALCYTE should be considered only if the potential benefits are judged to outweigh the risks.
Source: FDA drug label (Valcyte), NDA021304 (Cheplapharm), as published by H2-Pharma, LLC, effective December 8, 2025 (SPL set 4c517a39-2ded-4c5a-8d56-276853414b31), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Hydroxyurea | Valganciclovir | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma | n/a |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.184 per capsule 500 mg capsule | $1.91 per tablet 450 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once